BioSpace News Archive

Biotechs get scalable early to late phase clinical offering from Cromos Pharma and Avance Clinical collaboration in Australia and Europe

A team of researchers in Madrid, Spain, and another team in Toronto, Canada, are the first in the world to use focused ultrasound technology to target a new area of the brain in patients with Parkinson’s disease and potentially curb, or even reverse, its progression.

ProMIS Neurosciences, Inc. announced that co-founder and Chief Scientific Officer Dr. Neil Cashman will deliver a presentation titled “TDP-43 Misfolding-Specific Antibodies in Treatment of TDP-43 Mediated Diseases” on November 5th at the virtual ALS ONE Research Symposium.

Epizyme, a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, announced that management will host a conference call and webcast to discuss its third quarter 2020 financial results and other business highlights on Friday, Nov. 6, 2020 at 8:00 a.m. ET.

Magellan Rx Management LLC, Earns Full Accreditation in Health Utilization Management (HUM) Magellan Rx Pharmacy LLC, Earns Full Specialty Pharmacy Distribution (SPD) Accreditation

Data support baricitinib’s ongoing Phase 3 program and potential to be the first approved medicine for people living with alopecia areata (AA)

NovaBay® Pharmaceuticals, Inc. announces it will report financial results for the three and nine months ended September 30, 2020 after market close on Thursday, November 12, 2020 and will hold an investment community conference call that day at 4:30 p.m. Eastern time.

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, announced that it will release its third quarter 2020 financial results and operational highlights before open of U.S. markets on Thursday, November 5, 2020.

Updated data on analytical technologies for determining the proportion of AAV capsids containing full-length vector genomes

Iovance Biotherapeutics, Inc., a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report its third quarter 2020 financial results on Thursday, Nov. 5, 2020.